School of Medical Informatics, Chongqing Medical University, Chongqing, China.
Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
BMJ Open. 2024 Nov 20;14(11):e087113. doi: 10.1136/bmjopen-2024-087113.
The aim of this study is to assess cost-effectiveness of robotic radical hysterectomy (RRH) vs laparoscopic radical hysterectomy (LRH) in early-stage cervical cancer (ECC).
Model-based cost-effectiveness analysis.
Based on long-term survival data, a three-state Markov model was constructed using TreeAge Pro 2022 to simulate the possible recurrence of ECC. Data on clinical efficacy and costs were derived from published literature and local databases.
A hypothetical cohort of 1000 individuals diagnosed with early-stage cervical cancer (FIGO 2009 stages<IIB) who underwent RRH or LRH management.
The study endpoints were quality-adjusted life years (QALYs), total costs (in Chinese renminbi (RMB) adjusted to 2023-year values using the Consumer Price Index) and incremental cost-effectiveness ratio (ICER). A willingness-to-pay threshold of 268 074 RMB per QALY was used to assess cost-effectiveness.
Robotic group gained more 4.84 QALYs than the laparoscopic group, but total costs for robotic strategy are substantially higher, with the incremental costs of 1 031 108 RMB. The ICER of robotic strategy is 213 054 RMB per QALY. Outcomes were robust in most one-way sensitivity and probabilistic sensitivity analyses.
Robotic strategy is on the efficient frontier but incurs substantial initial cost. Our findings indicated that this strategy is a cost-effective treatment option for ECC patients if assessed over a time horizon of patients' lifetime. This study underscores the need for long-term clinical trials in early-stage cervical cancer patients with follow-up data that capture financial and quality-of-life end points.
本研究旨在评估早期宫颈癌(ECC)中机器人根治性子宫切除术(RRH)与腹腔镜根治性子宫切除术(LRH)的成本效果。
基于模型的成本效果分析。
基于长期生存数据,使用 TreeAge Pro 2022 构建了一个三状态马尔可夫模型,以模拟 ECC 的可能复发。临床疗效和成本数据来自已发表的文献和当地数据库。
假设 1000 名被诊断为早期宫颈癌(FIGO 2009 分期<IIB)的个体接受 RRH 或 LRH 管理。
研究终点为质量调整生命年(QALYs)、总费用(以人民币(RMB)表示,使用消费者价格指数调整至 2023 年)和增量成本效果比(ICER)。使用 268074 元人民币/QALY 的意愿支付阈值来评估成本效果。
机器人组比腹腔镜组多获得 4.84 个 QALYs,但机器人策略的总费用明显更高,增量成本为 1031108 元人民币。机器人策略的 ICER 为 213054 元人民币/QALY。在大多数单因素敏感性和概率敏感性分析中,结果都是稳健的。
机器人策略处于有效前沿,但会产生大量初始成本。我们的研究结果表明,如果在患者的整个生命周期内进行评估,机器人策略对于 ECC 患者来说是一种具有成本效益的治疗选择。这项研究强调了在早期宫颈癌患者中进行具有随访数据的长期临床试验的必要性,以捕获财务和生活质量终点。